论文部分内容阅读
流行性出血热(EHF)目前缺乏完全有效的治疗措施。Ⅰ型变态反应参与EHF早期病理过程,EHF病毒作为致病因子可诱导变态反应,以Ⅰ型变态反应为先导,引起早期损伤,并为中晚期循环免疫复合物(CIC)的沉积与致病创造了条件,已证实中晚期EHF血中有大量CIC。据此设计的联合抗过敏疗法治疗发热期病人行之有效。我们又依据红细胞有排出CIC的功能,补体有降解CIC的功能,设计了联合抗过敏疗法加新鲜血液治疗中晚期EHF患
Epidemic hemorrhagic fever (EHF) currently lacks a fully effective treatment. Type I allergic reactions are involved in the early pathological process of EHF. EHF virus can induce allergic reaction as a causative agent and lead to type I allergic reaction, which leads to early injury. It is also used for the deposition and pathogenesis of intermediate and late circulating immune complex (CIC) The conditions, it has been confirmed in the late EHF blood CIC. According to the design of the joint anti-allergy therapy for patients with fever effective. We are also based on the function of red blood cells to discharge CIC, complement CIC degradation of the function of the design of a combination of anti-allergy therapy plus fresh blood treatment of advanced EHF